RxDoctor Payments Data

Kelly Lee, MD

Ophthalmology · Malta, NYNPI 1841722279

Payments from drug & device makers

$3,064in general payments, 2019–2025

Across 84 payments — averaging $36.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$753
  • Alcon$706
  • Dompe US, Inc.$301
  • Amgen$192
  • Oyster Point Pharma, Inc.$162
  • Biotissue Holdings Inc.$158
  • plus $792 from 8 others

What the payments were for

  • Food & beverage$3,064100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,064 in reported general payments places this provider in the 65th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$161,598
Medicare patients
584
Services billed
1,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine49$68,873
LumiganBimatoprost41$28,678
Cyclosporine33$17,718
TyrvayaVarenicline Tartrate21$16,254
RocklatanNetarsudil Mesylat/Latanoprost16$14,075
VyzultaLatanoprostene Bunod13$9,188
SimbrinzaBrinzolamide/Brimonidine Tart24$7,219
CombiganBrimonidine Tartrate/Timolol11$6,254
Brimonidine Tartrate94$4,476
Prednisolone Acetate107$3,804
Travoprost27$2,969
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$2,955
Brinzolamide12$2,330
Latanoprost196$2,294
Bromfenac Sodium15$1,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$753$103,805101 claims
Oyster Point Pharma, Inc.Tyrvaya$162$16,25421 claims
Bausch & Lomb Americas Inc.Vyzulta$107$9,18813 claims
AlconSimbrinza$706$7,21924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Malta

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →